ProVascTec develops medical devices focused on vascular health, targeting conditions that require precise vessel repair or regeneration. Its technology platform integrates biomaterials and delivery systems to enable minimally invasive treatment of arterial and venous diseases. The company aims to improve patient outcomes by providing clinicians with reliable, scalable solutions for vascular interventions.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
EFounders
Product
Problem
Current cardiovascular interventions often face limitations in efficacy and long-term outcomes, leading to complications and hospital readmissions. Existing treatments may not adequately address the underlying causes of cardiovascular disease or provide targeted drug delivery to affected areas. This results in suboptimal patient outcomes and a reduced quality of life for individuals with cardiovascular conditions.
Solution
ProVascTecs develops targeted therapies for cardiovascular complications by leveraging advanced biomaterials and drug delivery systems. Their approach aims to enhance treatment efficacy by precisely delivering therapeutic agents to the affected areas within the cardiovascular system. By addressing the limitations of current interventions, ProVascTecs seeks to improve patient outcomes, reduce the incidence of complications, and minimize hospital readmissions. The company's technology focuses on providing tailored solutions that directly target the underlying causes of cardiovascular disease, leading to more effective and sustainable results. This innovative approach has the potential to significantly improve the quality of life for patients with cardiovascular conditions.
Target Audience
The primary target audience includes patients with cardiovascular complications, as well as healthcare providers and hospitals specializing in cardiovascular care.
Features
- Advanced biomaterials for biocompatibility and targeted drug delivery.
- Drug delivery systems designed for precise and controlled release of therapeutic agents.
- Therapies focused on addressing the underlying causes of cardiovascular disease.
- Technology aimed at reducing complications and hospital readmissions associated with cardiovascular interventions.